Human papillomavirus vaccination: The population impact

F1000Research

Volumn 6, Issue , 2017, Pages

  Garland, Suzanne M ^a,b,c,d   Lee, Lai yang ^a,b  

^a ROYAL WOMEN'S HOSPITAL   (Australia)

^b ROYAL CHILDREN'S HOSPITAL   (Australia)

^c MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Cervical cancer; HPV vaccination; Prevention; Prophylactics

Indexed keywords

WART VIRUS VACCINE;

CANCER INCIDENCE; COMPLEX REGIONAL PAIN SYNDROME; CONDYLOMA ACUMINATUM; DRUG EFFICACY; DRUG WITHDRAWAL; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; NONHUMAN; PAPILLOMAVIRUS INFECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POPULATION RESEARCH; PRACTICE GUIDELINE; PREVENTIVE HEALTH SERVICE; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SEXUALITY; TREATMENT OUTCOME; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; VIRUS TRANSMISSION;

EID: 85024497354     PISSN: 20461402     EISSN: 1759796X     Source Type: Journal    
DOI: 10.12688/f1000research.10691.1     Document Type: Review

References (104)

1. Forman D de Martel C Lacey CJ: Global burden of human papillomavirus and related diseases. Vaccine. 2012;30(Suppl 5):F12-23. 23199955 10.1016/j.vaccine.2012.07.055
2. Walboomers JM Jacobs MV Manos MM: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12-9. 10451482 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F
3. Giuliano AR Harris R Sedjo RL: Incidence, prevalence, and clearance of type-specific human papillomavirus infections: The Young Women's Health Study. J Infect Dis. 2002;186(4):462-9. 12195372 10.1086/341782
4. Monsonego J Bosch FX Coursaget P: Cervical cancer control, priorities and new directions. Int J Cancer. 2004;108(3):329-33. 14648697 10.1002/ijc.11530
5. Wright TC Jr: Natural history of HPV infections. J Fam Pract. Quadrant Healthcom, Inc;2009;58(9 Suppl HPV):S3-7. 19744423
6. Gravitt PE: Evidence and impact of human papillomavirus latency. Open Virol J. 2012;6(Suppl 2):198-203. 23341855 10.2174/1874357901206010198 3547385
7. Hampton T: Nobel Prize honors HIV, HPV discoveries. JAMA. 2008;300(18):2109. 19001616 10.1001/jama.2008.616
8. Clifford GM Smith JS Plummer M: Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer. 2003;88(1):63-73. 12556961 10.1038/sj.bjc.6600688 2376782
9. World Health Organisation: Media Centre: Human Papillomavirus(HPV) and cervical cancer.2016. Reference Source
10. Garland SM Steben M Sings HL: Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis. 2009;199(6):805-14. 19199546 10.1086/597071 F1000 Recommendation
11. Somers GR Tabrizi SN Borg AJ: Juvenile laryngeal papillomatosis in a pediatric population: a clinicopathologic study. Pediatr Pathol Lab Med. 1997;17(1):53-64. 9050060 10.1080/107710497175029
12. Wheeler CM Castellsagué X Garland SM: Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012;13(1):100-10. 22075170 10.1016/S1470-2045(11)70287-X
13. Lehtinen M Paavonen J Wheeler CM: Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012;13(1):89-99. 22075171 10.1016/S1470-2045(11)70286-8 F1000 Recommendation
14. Garland SM Hernandez-Avila M Wheeler CM: Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356(19):1928-43. 17494926 10.1056/NEJMoa061760 F1000 Recommendation
15. FUTURE II Study Group: Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356(19):1915-27. 17494925 10.1056/NEJMoa061741 F1000 Recommendation
16. Joura EA Giuliano AR Iversen OE: A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372(8):711-23. 25693011 10.1056/NEJMoa1405044
17. Brisson M Bénard É Drolet M: Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: A systematic review and meta-analysis of predictions from transmission-dynamic models. Lancet Public Health. 2016;1(1):e8-e17. 10.1016/S2468-2667(16)30001-9 F1000 Recommendation
18. Drolet M Bénard E Boily MC: Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis. 2015;15(5):565-80. 25744474 10.1016/S1473-3099(14)71073-4 5144106 F1000 Recommendation
19. Poljak M Kocjan BJ Oštrbenk A: Commercially available molecular tests for human papillomaviruses (HPV): 2015 update. J Clin Virol. 2016;76(Suppl 1):S3-S13. 26601820 10.1016/j.jcv.2015.10.023 F1000 Recommendation
20. Snijders PJ van den Brule AJ Meijer CJ: The clinical relevance of human papillomavirus testing: relationship between analytical and clinical sensitivity. J Pathol. 2003;201(1):1-6. 12950011 10.1002/path.1433
21. Pagliusi SR Garland SM: International standard reagents for HPV detection. Dis Markers. 2007;23(4):283-96. 17627063 10.1155/2007/591826 3851336
22. Garland SM Kjaer SK Muñoz N: Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world Experience. Clin Infect Dis. 2016;63(4):519-27. 27230391 10.1093/cid/ciw354 4967609
23. Garland SM Skinner SR Brotherton JM: Adolescent and young adult HPV vaccination in Australia: achievements and challenges. Prev Med. 2011;53(Suppl 1):S29-35. 21962468 10.1016/j.ypmed.2011.08.015
24. Garland SM Molesworth EG Machalek DA: How to best measure the effectiveness of male human papillomavirus vaccine programmes? Clin Microbiol Infect. 2015;21(9):834-41. 26055415 10.1016/j.cmi.2015.05.038
25. National HPV Vaccination Program Register: HPV vaccination coverage by dose number (Australia) for males by age group in mid 2014. [cited 2017 Jan 8]. Reference Source
26. Brotherton JM Liu B Donovan B: Human papillomavirus (HPV) vaccination coverage in young Australian women is higher than previously estimated: independent estimates from a nationally representative mobile phone survey. Vaccine. 2014;32(5):592-7. 24316239 10.1016/j.vaccine.2013.11.075 F1000 Recommendation
27. Tabrizi SN Brotherton JM Kaldor JM: Fall in human papillomavirus prevalence following a national vaccination program. J Infect Dis. 2012;206(11):1645-51. 23087430 10.1093/infdis/jis590 F1000 Recommendation
28. Tabrizi SN Brotherton JM Kaldor JM: Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study. Lancet Infect Dis. 2014;14(10):958-66. 25107680 10.1016/S1473-3099(14)70841-2
29. Machalek DA Chow EP Garland SM: Human Papillomavirus Prevalence in Unvaccinated Heterosexual Men After a National Female Vaccination Program. J Infect Dis. 2017;215(2):202-8. 27815379 10.1093/infdis/jiw530
30. Kavanagh K Pollock KG Potts A: Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types. Br J Cancer. 2014;110(11):2804-11. 24736582 10.1038/bjc.2014.198 4037824 F1000 Recommendation
31. Markowitz LE Hariri S Lin C: Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010. J Infect Dis. 2013;208(3):385-93. 23785124 10.1093/infdis/jit192 F1000 Recommendation
32. Markowitz LE Liu G Hariri S: Prevalence of HPV After Introduction of the Vaccination Program in the United States. Pediatrics. 2016;137(3):e20151968. 26908697 10.1542/peds.2015-1968 F1000 Recommendation
33. Berenson AB Laz TH Rahman M: Reduction in Vaccine-Type Human Papillomavirus Prevalence Among Women in the United States, 2009-2012. J Infect Dis. 2016;214(12):1961-4. 27821406 10.1093/infdis/jiw515 F1000 Recommendation
34. Kjaer SK Tran TN Sparen P: The burden of genital warts: a study of nearly 70,000 women from the general female population in the 4 Nordic countries. J Infect Dis. 2007;196(10):1447-54. 18008222 10.1086/522863
35. Donovan B Franklin N Guy R: Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect Dis. 2011;11(1):39-44. 21067976 10.1016/S1473-3099(10)70225-5 F1000 Recommendation
36. Read TR Hocking JS Chen MY: The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme. Sex Transm Infect. 2011;87(7):544-7. 21970896 10.1136/sextrans-2011-050234 F1000 Recommendation
37. Ali H Donovan B Wand H: Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ. 2013;346:f2032. 23599298 10.1136/bmj.f2032 F1000 Recommendation
38. Howell-Jones R Soldan K Wetten S: Declining genital Warts in young women in england associated with HPV 16/18 vaccination: an ecological study. J Infect Dis. 2013;208(9):1397-403. 24092908 10.1093/infdis/jit361 3789575
39. Szarewski A Skinner SR Garland SM: Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against low-risk HPV types (PATRICIA randomized trial): an unexpected observation. J Infect Dis. 2013;208(9):1391-6. 24092907 10.1093/infdis/jit360 3789574
40. Dochez C Bogers JJ Verhelst R: HPV vaccines to prevent cervical cancer and genital warts: an update. Vaccine. 2014;32(14):1595-601. 24606637 10.1016/j.vaccine.2013.10.081 F1000 Recommendation
41. Baandrup L Blomberg M Dehlendorff C: Significant decrease in the incidence of genital warts in young Danish women after implementation of a national human papillomavirus vaccination program. Sex Transm Dis. 2013;40(2):130-5. 23324976
42. Bollerup S Baldur-Felskov B Blomberg M: Significant Reduction in the Incidence of Genital Warts in Young Men 5 Years into the Danish Human Papillomavirus Vaccination Program for Girls and Women. Sex Transm Dis. 2016;43(4):238-42. 26967300 10.1097/OLQ.0000000000000418 F1000 Recommendation
43. Blomberg M Dehlendorff C Munk C: Strongly decreased risk of genital warts after vaccination against human papillomavirus: nationwide follow-up of vaccinated and unvaccinated girls in Denmark. Clin Infect Dis. 2013;57(7):929-34. 23804192 10.1093/cid/cit436
44. Dominiak-Felden G Gobbo C Simondon F: Evaluating the Early Benefit of Quadrivalent HPV Vaccine on Genital Warts in Belgium: A Cohort Study. PLoS One. 2015;10(7):e0132404. 26147096 10.1371/journal.pone.0132404 4492693 F1000 Recommendation
45. Australian Government. Australian Insititue of Health and Welfare: Cervical screening in Australia 2013-2014. [cited 2017 Jan 8]. Reference Source
46. Brotherton JM Fridman M May CL: Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet. 2011;377(9783):2085-92. 21684381 10.1016/S0140-6736(11)60551-5
47. Gertig DM Brotherton JM Budd AC: Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study. BMC Med. 2013;11:227. 24148310 10.1186/1741-7015-11-227 4015688
48. Brotherton JM Saville AM May CL: Human papillomavirus vaccination is changing the epidemiology of high-grade cervical lesions in Australia. Cancer Causes Control. 2015;26(6):953-4. 25804857 10.1007/s10552-015-0568-6
49. Pollock KG Kavanagh K Potts A: Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland. Br J Cancer. 2014;111(9):1824-30. 25180766 10.1038/bjc.2014.479 4453734 F1000 Recommendation
50. Baldur-Felskov B Dehlendorff C Munk C: Early impact of human papillomavirus vaccination on cervical neoplasia--nationwide follow-up of young Danish women. J Natl Cancer Inst. 2014;106(3):djt460. 24552678 10.1093/jnci/djt460 F1000 Recommendation
51. Baldur-Felskov B Dehlendorff C Junge J: Incidence of cervical lesions in Danish women before and after implementation of a national HPV vaccination program. Cancer Causes Control. 2014;25(7):915-22. 24797870 10.1007/s10552-014-0392-4 F1000 Recommendation
52. Baldur-Felskov B Munk C Nielsen TS: Trends in the incidence of cervical cancer and severe precancerous lesions in Denmark, 1997-2012. Cancer Causes Control. 2015;26(8):1105-16. 26033777 10.1007/s10552-015-0603-7 F1000 Recommendation
53. Skinner SR Apter D De Carvalho N: Human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for the prevention of cervical cancer and HPV-related diseases. Expert Rev Vaccines. 2016;15(3):367-87. 26902666 F1000 Recommendation
54. Australian Government Cancer Australia: Cervical cancer in Australia. [cited2017Jan 8]. Reference Source
55. Cancer Research UK: Cervical cancer incidence statistics. [cited 2017 Mar 21]. Reference Source
56. van Kriekinge G Castellsague X Cibula D: Estimation of the potential overall impact of human papillomavirus vaccination on cervical cancer cases and deaths. Vaccine. 2014;32(6):733-9. 24291200 10.1016/j.vaccine.2013.11.049 https://f1000.com/prime/718195125
57. Riethmuller D Jacquard A Lacau St Guily J: Potential impact of a nonavalent HPV vaccine on the occurrence of HPV-related diseases in France. BMC Public Health. 2015;15:453. 25934423 10.1186/s12889-015-1779-1 4433025 https://f1000.com/prime/725583719
58. Luckett R Feldman S: Impact of 2-, 4- and 9-valent HPV vaccines on morbidity and mortality from cervical cancer. Hum Vaccin Immunother. 2016;12(6):1332-42. 26588179 10.1080/21645515.2015.1108500 4964711 https://f1000.com/prime/725953428
59. Buchanan TR Graybill WS Pierce JY: Morbidity and mortality of vulvar and vaginal cancers: Impact of 2-, 4-, and 9-valent HPV vaccines. Hum Vaccin Immunother. 2016;12(6):1352-6. 26901390 10.1080/21645515.2016.1147634 4964646 https://f1000.com/prime/727619891
60. Stier EA Chigurupati NL Fung L: Prophylactic HPV vaccination and anal cancer. Hum Vaccin Immunother. 2016;12(6):1348-51. 26933898 4964669 https://f1000.com/prime/727619892
61. National HPV Vaccination Program Register: HPV Vaccination Coverage. [cited 2017 Jan 13]. Reference Source
62. Garland SM: The Australian experience with the human papillomavirus vaccine. Clin Ther. 2014;36(1):17-23. 24417782 10.1016/j.clinthera.2013.12.005
63. Oliver K Frawley A Garland E: HPV vaccination: Population approaches for improving rates. Hum Vaccin Immunother. 2016;12(6):1589-93. 26890685 10.1080/21645515.2016.1139253 4964670
64. Gee J Weinbaum C Sukumaran L: Quadrivalent HPV vaccine safety review and safety monitoring plans for nine-valent HPV vaccine in the United States. Hum Vaccin Immunother. 2016;12(6):1406-17. 27029786 10.1080/21645515.2016.1168952 4964727 https://f1000.com/prime/726257863
65. Naud PS Roteli-Martins CM Carvalho NS: Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination. Hum Vaccin Immunother. 2014;10(8):2147-62. 25424918 10.4161/hv.29532 4896780 https://f1000.com/prime/725251333
66. Garland SM Stanley M Brotheron J: IPVS Policy statement on safety of HPV vaccines. Papillomavirus Res. 2016;2:9-10. 10.1016/j.pvr.2015.11.001
67. Centers for Disease Control and Prevention: Frequently asked Questions about HPV Vaccine Safety. [cited 2017 Mar 13]. Reference Source
68. Larson HJ Wilson R Hanley S: Tracking the global spread of vaccine sentiments: the global response to Japan's suspension of its HPV vaccine recommendation. Hum Vaccin Immunother. 2014;10(9):2543-50. 25483472 10.4161/21645515.2014.969618 4977439
69. Tanaka Y Ueda Y Egawa-Takata T: Outcomes for girls without HPV vaccination in Japan. Lancet Oncol. 2016;17(7):868-9. 27396634 10.1016/S1470-2045(16)00147-9
70. Hanley SJ Yoshioka E Ito Y: HPV vaccination crisis in Japan. Lancet. 2015;385(9987):2571. 26122153 10.1016/S0140-6736(15)61152-7
71. Vichnin M Bonanni P Klein NP: An Overview of Quadrivalent Human Papillomavirus Vaccine Safety: 2006 to 2015. Pediatr Infect Dis J. 2015;34(9):983-91. 26107345 10.1097/INF.0000000000000793
72. Safety of HPV Vaccines: Global Vaccine Safety. [Internet]. [cited 2017 Jan 8]. Reference Source
73. World Health Organisation: Immunisation, Vaccines and Biologicals: Human Papillomavirus (HPV).2016, [cited 2017 Jan 3]. Reference Source
74. Centers for Disease Control and Prevention: Human Papillomavirus (HPV) Vaccine Safety. [cited 2017 Jan 14]. Reference Source
75. Stanley M: Immune responses to human papillomavirus. Vaccine. 2006;24(Suppl 1):S16-22. 16219398 10.1016/j.vaccine.2005.09.002 F1000 Recommendation
76. Basu P Bhatla N Ngoma T: Less than 3 doses of the HPV vaccine-Review of efficacy against virological and disease end points. Hum Vaccin Immunother. 2016;12(6):1394-402. 26933961 10.1080/21645515.2016.1146429 4964672
77. Australian Technical Advisory Group on Immunisation (ATAGI): The Australian Immunisation Handbook 10th ed (2016 update). Canberra: Australian Government Department of Health.2016. Reference Source
78. Smith MA Lew JB Walker RJ: The predicted impact of HPV vaccination on male infections and male HPV-related cancers in Australia. Vaccine. 2011;29(48):9112-22. 21419773 10.1016/j.vaccine.2011.02.091
79. Smith MA Canfell K: Incremental benefits of male HPV vaccination: accounting for inequality in population uptake. PLoS One. 2014;9(8):e101048. 25089637 10.1371/journal.pone.0101048 4121069 F1000 Recommendation
80. Largeron N Petry KU Jacob J: An estimate of the public health impact and cost-effectiveness of universal vaccination with a 9-valent HPV vaccine in Germany. Expert Rev Pharmacoecon Outcomes Res. 2017;17(1):85-98. 27366939 10.1080/14737167.2016.1208087 F1000 Recommendation
81. Drolet M Laprise JF Boily MC: Potential cost-effectiveness of the nonavalent human papillomavirus (HPV) vaccine. Int J Cancer. 2014;134(9):2264-8. 24174175 10.1002/ijc.28541 F1000 Recommendation
82. Skinner SR Szarewski A Romanowski B: Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet. 2014;384(9961):2213-27. 25189358 10.1016/S0140-6736(14)60920-X
83. Wheeler CM Skinner SR Del Rosario-Raymundo MR: Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet Infect Dis. 2016;16(10):1154-68. 27373900 10.1016/S1473-3099(16)30120-7
84. Munoz N Manalastas R Jr Pitisuttithum P: Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet. 2009;373(9679):1949-57. 19493565 10.1016/S0140-6736(09)60691-7 F1000 Recommendation
85. Haupt RM Wheeler CM Brown DR: Impact of an HPV6/11/16/18 L1 virus-like particle vaccine on progression to cervical intraepithelial neoplasia in seropositive women with HPV16/18 infection. Int J Cancer. 2011;129(11):2632-42. 21491420 10.1002/ijc.25940
86. Olsson SE Kjaer SK Sigurdsson K: Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum Vaccin. 2009;5(10):696-704. 19855170 10.4161/hv.5.10.9515
87. Szarewski A Poppe WA Skinner SR: Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16/18. Int J Cancer. 2012;131(1):106-16. 21858807 10.1002/ijc.26362
88. Bosch FX Robles C Díaz M: HPV-FASTER: broadening the scope for prevention of HPV-related cancer. Nat Rev Clin Oncol. 2016;13(2):119-32. 26323382 10.1038/nrclinonc.2015.146
89. Brotherton JM Kaldor JM Garland SM: Monitoring the control of human papillomavirus (HPV) infection and related diseases in Australia: towards a national HPV surveillance strategy. Sex Health. 2010;7(3):310-9. 20719220 10.1071/SH09137
90. Stubbs R: Public Health England Screening-HPV primary screening in the cervical screening programme. [cited 2017 Mar 13]. Reference Source
91. ICO Information Centre on HPV and Cancer. hpvcentre.net. [cited 2017 Jan 13]. Reference Source
92. Centers for Disease Control and Prevention: Human Papillomavirus (HPV). [cited 2017 Jan 8]. Reference Source
93. Centers for Disease Control and Prevention: Human Papillomavirus(HPV)ACIP Vaccine Recommendations. [cited 2017 Jan 13]. Reference Source
94. National, Regional State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13-17years-United States 2015 MMWR Aug 26 2016. [cited 2017 Jan 13]. Reference Source
95. NIH National Cancer Institute: Human Papillomavirus (HPV) Vaccine. 2016, [cited 2017 Jan 13]. Reference Source
96. Powell SE Hariri S Steinau M: Impact of human papillomavirus (HPV) vaccination on HPV 16/18-related prevalence in precancerous cervical lesions. Vaccine. 2012;31(1):109-13. 23137842 10.1016/j.vaccine.2012.10.092
97. NHS: HPV Vaccine.2014, [cited 2017 Jan 13]. Reference Source
98. NHS: Cervical screening.2015, [cited 2017 Jan 13]. Reference Source
99. Public Health England: Human Papillomavirus (HPV) Vaccine Coverage in England, 2008/09 to 2013/14, A review of the full six years of the three-dose schedule.2015, [cited 2017 Jan 13]. Reference Source
100. Public Health England: HPR volume 10 issue 22:news (8July). [cited 2017 Jan 13]. Reference Source
101. ICO Information Centre on HPV and Cancer: Human Papillomavirus and Related Diseases Report: Denmark, December 15 2016. Reference Source
102. Blomberg M Dehlendorff C Sand C: Dose-Related Differences in Effectiveness of Human Papillomavirus Vaccination Against Genital Warts: A Nationwide Study of 550,000 Young Girls. Clin Infect Dis. 2015;61(5):676-82. 25944340 10.1093/cid/civ364
103. Immunisation Scotland: HPV Vaccine.2016, [cited 2017 Jan 13]. Reference Source
104. Information Services Division Publication Report: HPV Immunisation Statistics Scotland, School year 2015/2016.2016, [cited 2017 Jan 13]. Reference Source